セリザワ ナオキ   SERIZAWA Naoki
  芹澤 直紀
   所属   医学部 医学科(東京女子医科大学病院)
   職種   助教
言語種別 英語
発表タイトル Atrial Arrhythmia is a Marker of Disease Progression in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia
会議名 The 79th Annual Scientific Meeting of the Japanese Circulation Society
主催者 Japanese Circulation Society
学会区分 全国規模の学会
発表形式 ポスター掲示
講演区分 一般
発表者・共同発表者◎KIKUCHI Noriko, TOBITA Naoshige, HATTORI Hidetoshi, SERIZAWA Naoki, SUZUKI Atsushi, YUMINO Dai, SUZUKI Tsuyoshi, SHIGA Tsuyoshi, SHODA Morio, HAGIWARA Nobuhisa
発表年月日 2015/04/24
開催地
(都市, 国名)
Osaka, JAPAN
学会抄録 PROGRAM JCS 2015 207
概要 Background: Clinical observation suggests that arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) could have varying four clinical phases: concealed phase, electrical phase, failure phase and end-stage phase. Although the role of atrial arrhythmia in ARVC/D has been neglected, it sometimes occurs in the later phases of this disease and may serve as a predictor of the prognosis in this condition.Methods and Results: Ninety patients with ARVC/D treated at a tertiary center in Japan between 1974 and 2012 were enrolled following their assessment based on the major and minor criteria in the revised 2010 Task Force Criteria. Patients were followed up to determine adverse outcomes (life-threatening ventricular arrhythmia, heart failure hospitalization, and all-cause death). During the follow-up period of 10.2±7.1 years, 47 patients experienced ventricular arrhythmia after a mean of 4.5±5.1 years, 28 were hospitalized for heart failure after a mean of 10.2±5.8 years and 21 patients died after a mean of 11.2±6.5 years from diagnosis or initial evaluation. Of 26 hospitalized HF patients (excluding two patients with incomplete data regarding atrial arrhythmia), 22 (85%) experienced some form of atrial arrhythmia around HF admission.Conclusion: The occurrence of atrial arrhythmia may predict progression of the disease to the failure phase in ARVC/D. Furthermore, the management of atrial arrhythmia may be crucial to the success of therapy in the later phases of the disease.